Now that the general public has been conditioned to accept that Ebola can only be stopped through immediate intervention with magic drugs and vaccines from the West, British vaccine giant GlaxoSmithKline (GSK) is readying to begin tests on an experimental Ebola vaccine, which reports indicate will be given to unsuspecting healthcare workers in Mali.
Though there have been no reported Ebola cases in Mali, GSK is fast-tracking its vaccine, known as cAd3-ZEBOV, with the blessing of the World Health Organization (WHO), for rapid approval in early 2015. Normally, the preliminary testing process alone would take up to a year, but ongoing Ebola propaganda has facilitated a “lightning speed” approval process that appears to have been the goal of the Ebola “crisis” all along.
According to FierceVaccines, a total of 40 healthcare workers in Mali will receive the experimental Ebola vaccine, which GSK developed in conjunction with the Vaccine Research Center (VRC) and the National Institute of Allergy and Infectious Diseases (NIAID). Mali’s Center for Vaccine Development and Ministry of Health are both onboard as well.